Immunovant
Rebecca Merlina is an experienced leader in quality and regulatory compliance within the biopharmaceutical sector. Currently serving as SVP and Global Head of Quality at Immunovant, Rebecca has held significant roles at several notable companies, including Vice President of Quality & Regulatory for the Clinical Trials Division at Thermo Fisher Scientific. Prior experience includes Head of R&D Quality at Advanced Accelerator Applications, Vice President of Quality at Endocyte, and multiple positions at Eli Lilly and Company, where responsibilities encompassed global quality auditing, compliance, and regulatory affairs quality assurance.
This person is not in any teams
This person is not in any offices
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.